Saumya Das, MD, PhD is a Professor of Medicine at Harvard Medical School, a faculty member of the Cardiac Arrhythmia Service and the co-Director of the Arrhythmia Genetics Clinic at Massachusetts General Hospital.

Dr. Das completed his undergraduate training at Harvard College, graduating summa cum laude in Biology. He completed his MD-PhD training at Harvard Medical School (in the Health Sciences and Technology pathway) with his PhD in neurobiology. Following residency in internal medicine and fellowship training in cardiovascular disease and clinical cardiac electrophysiology at MGH, he completed a research post-doctoral fellowship, studying signaling pathways in cardiac electrical remodeling. His research has focused on extracellular vesicles and their cargo RNAs as biomarkers in cardiometabolic and other diseases, functional characterization of novel non-coding RNAs in heart and kidney disease, and RNA-based therapeutics.

He has been the lead PI of several National Center for Advanced Translation (NCAT) grants to discover and validate RNA biomarkers of heart remodeling in heart failure. As part of the NIH Extracellular RNA Communication Consortium he has served as a co-chair of the steering committee. He was inducted in the American Society of Clinical Investigation in 2020 and received an NIH EIA award (R35). He is on the advisory board for American Association of Extracellular Vesicles and was the meeting chair for the inaugural 2023 Annual Scientific Sessions for AAEV.

Work done in his laboratory has led to several patents. He is a cofounder of Thryv Therapeutics and Switch Therapeutics based on research done in his laboratory that seek to advance novel therapies for inherited arrhythmia syndromes, heart failure, and cardiac hypertrophy, with assets in Phase 2 trials.